ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1503

Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging

Craig Smuda1, Anna Eichinger2, Robert Clancy2, Jill Buyon3 and Boris Reizis4, 1NYU Grossman School of Medic ine, New York, NY, 2NYU Grossman School of Medicine, New York, NY, 3NYU School of Medicine, New York, NY, 4New York University Grossman School of Medicine, New York, NY

Meeting: ACR Convergence 2021

Keywords: Imaging, immunology, Lupus nephritis, Nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: SLE – Etiology & Pathogenesis Poster (1480–1506)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The Accelerating Medicines Project (AMP) has enabled significant increases in understanding of SLE nephritis pathology, providing a profile of dozens of leukocyte subsets within affected kidneys by single-cell RNA sequencing of nephritis biopsies. While these results suggest a complex network of interactions between cell populations during nephritis, the spatial positioning of these cells is lost during the sequencing process. Inferred interactions between the diverse identified cell types would be greatly strengthened by detailed spatial information, placing these cells in context with each other and with the surrounding structures of the kidney.

Methods: In consultation with AMP, we have used CODEX, a multicycle imaging technology allowing for staining of up to 40 targets on a single tissue sample without tissue degradation, to capture preliminary images of the AMP tissue biopsies available at New York University. Extensive antibody screening, sample preparation, optimization of antigen retrieval, and imaging steps are required, which remain under active optimization to allow for imaging the entirety of the AMP biopsy cohort available at the Grossman School of Medicine, which has been fully processed for future staining.

Results: At present we are able to image sixteen targets capturing dense interstitial T and B cell infiltrates, intratubular and interstitial myeloid populations, and sparser glomerular infiltrating cells in our demonstration cohort, with clear imaging of the glomeruli, tubules, and interstitial spaces. Further targets will be added as they are optimized, further allowing subsetting of T, B, and myeloid populations, with the goal of capturing the populations identified previously in single-cell sequencing.

Conclusion: CODEX imaging of renal biopsy samples provides spatial context for prior observations across a range of SLE nephritis samples, with complex interstitial populations found around glomeruli and tubules in active disease. Deeper profiling with expanded antigen targets to enable further sub-population phenotyping and activation states and imaging of the full cohort of biopsies available at NYU will provide a spatial atlas to SLE nephritis and further reveal underlying mechanisms of disease.

A wide view of a selected biopsy demonstrates ultrastructure via multiple structural markers. Multiple such regions can be captured, allowing for the entirety of a biopsy sample to be imaged. All images shown display only a subset of the overall stained markers due to visual limitations.

Close examination of a tubule reveals diverse infiltrating cells, including CD11c+, CD11b/c+, and sparse CD11b/c+ HLA-DR+ cells. Surrounding interstitial lymphocytes can be seen, which correspond to CD3+ CD4+ T cells (stains not shown).

Periglomerular infiltration, without significant glomerular cellular involvement, is seen in this image. CD20+ B cells and HLA-DR+ cells can be seen in the lower left.


Disclosures: C. Smuda, None; A. Eichinger, None; R. Clancy, None; J. Buyon, Bristol Myers Squibb, 1, GlaxoSmithKline, 2, Janssen, 2, Ventus, 2, Equillium, 2; B. Reizis, None.

To cite this abstract in AMA style:

Smuda C, Eichinger A, Clancy R, Buyon J, Reizis B. Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/putting-the-pieces-on-the-board-mapping-sle-nephritis-biopsies-from-the-accelerating-medicines-project-using-high-density-immunofluorescence-imaging/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/putting-the-pieces-on-the-board-mapping-sle-nephritis-biopsies-from-the-accelerating-medicines-project-using-high-density-immunofluorescence-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology